Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

ung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The primary objective of the trial was to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN when administered in combination with gemcitabine. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

Gemzar(R) is indicated for NSCLC, breast, pancreatic and ovarian cancer. For more information about Gemzar(R), please visit www.gemzar.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. and U.S. combination REOLYSIN/gemcitabine clinical trials and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue researc
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... ... Confocal High-Content Imaging System. This transformative system fits a broad range of ... such as spheroids, tissues, and organisms. , The ImageXpress Micro Confocal ...
(Date:9/1/2015)... 2015 The Dohmen Company today announced ... MBA as Chief Science Officer (CSO) of Dohmen ... role, Dr. Floyd will lead Dohmen,s growing regulatory ... pre-commercial and post approval outsourced services in quality, ... Dr. Floyd brings decades of experience leading global ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Business Development, Asia Pacific. In this newly-created position, Gibbs will lead iLab’s business ... of iLab’s suite of tools. This entails not only introducing iLab to potential ...
(Date:9/1/2015)... , September 1, 2015 Shire plc ... Sara Mathew to its Board of Directors as ... the Audit, Compliance & Risk Committee of the Shire Board. ... Sara previously served as Chairman, President and Chief ... December 2013. During her 12-year tenure at D&B, she helped ...
Breaking Biology Technology:ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 2ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 3Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Shire Appoints Sara Mathew to Board of Directors 2
... THOUSAND OAKS, Calif., Dec. 6, 2011 Amgen (NASDAQ: ... and Drug Administration (FDA) has modified the requirements of ... Program. Prescribing physicians, patients and institutions are no longer ... the Nplate® NEXUS (Network of EXperts Understanding and Supporting ...
... GAITHERSBURG, Md., Dec. 6, 2011 GenVec, Inc. (Nasdaq: ... achieved the second milestone in its collaboration with Novartis ... of treatments for hearing loss and balance disorders. The ... preclinical development activities. "Completing this milestone ...
... elegant design, University at Buffalo chemists have synthesized tiny, ... purify nanomaterials. , Sculpted from a special kind of ... tiny, organic tubes whose interior walls carry a negative ... only positively charged particles. , In addition, because UB ...
Cached Biology Technology:Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 2Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 3Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 4Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 5Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 6Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 7Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy 8GenVec Achieves Second Milestone in Collaboration 2GenVec Achieves Second Milestone in Collaboration 3Chemists become molecular sculptors, synthesizing tiny, molecular traps 2Chemists become molecular sculptors, synthesizing tiny, molecular traps 3
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... company, has entered into an agreement with Panthera , ... For Life Leopard Project to ship faux leopard furs ... is ceremonially worn by followers of the Shembe community in ... on a pro bono basis faux leopard skins from manufacturers ...
... someone speak, we construct rich mental models that allow us ... states and contexts. This ability to understand written or spoken ... mind and central to everyday social life. In a new ... discourse comprehension. The study appears in Brain : ...
... brining your bird this Thanksgiving or experimenting with "wheat ... episode offers five tips on how to make this ... available now on http://www.BytesizeScience.com . Some traditions ... packed chemistry, you have plenty of room to experiment ...
Cached Biology News:DHL and Panthera partner to conserve South Africa's leopards 2DHL and Panthera partner to conserve South Africa's leopards 3Researchers map brain areas vital to understanding language 2
...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Jak3 Antibody Ship: Hot Store: -20 C...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: